Skip to main content

Advertisement

SpringerLink
Log in

HIV and Global Cardiovascular Health

  • Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Because of effective combination antiretroviral therapy, people living with HIV (PLWH) are living longer but developing chronic age-related conditions including cardiovascular disease (CVD), the leading cause of death globally. This review aims to discuss the epidemiology, mechanisms, and clinical considerations of CVD in PLWH from a global perspective.

Recent Findings

PLWH are at greater risk for CVD at chronologically younger ages than those without HIV. Potential underlying mechanisms for CVD in PLWH include systemic inflammation, comorbidities, immune-mediated, or treatment-related mechanisms. There is also risk factor variation based on geographical location, including non-traditional CVD risk factors.

Summary

CVD is prevalent in PLWH and increasing on a global scale. Further understanding the unique epidemiology, risk factors, and treatment of CVD in this population will improve the care of PLWH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. CONFRONTING INEQUALITIES: Lessons for pandemic responses from 40 years of AIDS [Internet]. GLOBAL AIDS UPDATE 2021; Available from: https://www.unaids.org/sites/default/files/media_asset/2021-global-aids-update_en.pdf

  2. Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:1005–70.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8: e81355.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339:405–6.

    Article  CAS  PubMed  Google Scholar 

  5. Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–97.

  6. •• Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis. Circulation. 2018;138:1100–12. Review analyzing the rate and risk of CVD in PLWH.

  7. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59:1891–6.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Post WS, Budoff M, Kingsley L, Palella FJ, Witt MD, Li X, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160:458–67.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228–30.

    Article  PubMed  Google Scholar 

  11. Nou E, Lo J, Hadigan C, Grinspoon SK. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol. 2016;4:598–610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, van Sighem A, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810–8.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dubé MP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118:198–210.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cerrato E, D’Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J. 2013;34:1432–6.

    Article  CAS  PubMed  Google Scholar 

  15. Sliwa K, Carrington MJ, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J. 2012;33:866–74.

  16. •• So-Armah K, Benjamin LA, Bloomfield GS, Feinstein MJ, Hsue P, Njuguna B, et al. HIV and cardiovascular disease. Lancet HIV. 2020;7:e279–93. Review highlighting the global variation in risk factors and future research needs in HIV associated CVD.

  17. Bijker R, Kumarasamy N, Kiertiburanakul S, Pujari S, Lam W, Chaiwarith R, et al. Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD). Antivir Ther. 2019;24:271–9.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61:511–23.

    Article  PubMed  Google Scholar 

  19. Bijker R, Choi JY, Ditangco R, Kiertiburanakul S, Lee MP, Siwamogsatham S, et al. Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region. Open AIDS J. 2017;11:52–66.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Joshi VV, Pawel B, Connor E, Sharer L, Oleske JM, Morrison S, et al. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol. 1987;7:261–75.

    CAS  PubMed  Google Scholar 

  21. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol. 1993;144:225–31.

    Article  CAS  PubMed  Google Scholar 

  22. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.

    Article  CAS  PubMed  Google Scholar 

  23. Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med. 2008;56:752–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.

    Article  CAS  PubMed  Google Scholar 

  25. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166:64–70.

    Article  CAS  PubMed  Google Scholar 

  26. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788–95.

    Article  CAS  PubMed  Google Scholar 

  27. Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, et al. HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent “PCSK9-lipid paradox.” J Am Heart Assoc. 2016;5: e002683.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Boccara F, Ghislain M, Meyer L, Goujard C, Le May C, Vigouroux C, et al. Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. AIDS. 2017;31:2367–76.

    Article  CAS  PubMed  Google Scholar 

  29. Leucker TM, Weiss RG, Schär M, Bonanno G, Mathews L, Jones SR, et al. Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV independent of low-density lipoprotein cholesterol. J Am Heart Assoc. 2018;7: e009996.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059–67.

    Article  CAS  PubMed  Google Scholar 

  31. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.

  32. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS ONE. 2016;11: e0155100.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Grunfeld C, Kotler DP, Shigenaga JK, Doerrler W, Tierney A, Wang J, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154–62.

    Article  CAS  PubMed  Google Scholar 

  34. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993;94:515–9.

    Article  PubMed  Google Scholar 

  35. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423–7.

    CAS  PubMed  Google Scholar 

  36. Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Li X-D, Dotterweich W, et al. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol. 2013;33:387–92.

    Article  CAS  PubMed  Google Scholar 

  37. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–82.

    Article  CAS  PubMed  Google Scholar 

  38. Sarkar S, Haberlen S, Whelton S, E Schneider E, Kingsley L, Palella F, et al. Greater IL-6, D-dimer, and ICAM-1 levels are associated with lower small HDL particle concentration in the multicenter AIDS cohort study. Open Forum Infect Dis. 2019;6:ofz474.

  39. Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.

    Article  PubMed  Google Scholar 

  40. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A d’Arminio, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35.

  41. Kajogoo VD, Gorret Atim M, Amare D, Geleta M, Muchie Y, Tesfahunei HA, et al. HIV protease inhibitors and insulin sensitivity: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12: 635089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral- therapy-naive patients infected with HIV-1. PLoS Med. 2004;1: e19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 1997;127:947.

    Article  CAS  PubMed  Google Scholar 

  44. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet. 1997;350:713–4.

    Article  PubMed  Google Scholar 

  45. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881–3.

    Article  CAS  PubMed  Google Scholar 

  46. Zhou H, Pandak WM, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol. 2005;68:690–700.

    Article  CAS  PubMed  Google Scholar 

  47. Allred KF, Smart EJ, Wilson ME. Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors. J Biol Chem. 2006;281:1419–25.

    Article  CAS  PubMed  Google Scholar 

  48. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318–30.

    Article  CAS  PubMed  Google Scholar 

  49. Lakey W, Yang L-Y, Yancy W, Chow S-C, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses. 2013;29:435–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS ONE. 2010;5: e10106.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32:50–8.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Sarkar S, Brown TT. Diabetes in People with HIV. Curr Diab Rep. 2021;21:13.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017;11:530–40.

    Article  PubMed  Google Scholar 

  54. Raposeiras-Roubín S, Abu-Assi E, Iñiguez-Romo A. Tobacco, illicit drugs use and risk of cardiovascular disease in patients living with HIV. Curr Opin HIV AIDS. 2017;12:523–7.

    Article  PubMed  Google Scholar 

  55. Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727–34.

    Article  PubMed  Google Scholar 

  56. Nduka CU, Uthman OA. Drug abuse in people living with HIV in the era of highly active antiretroviral therapy: a systematic review and meta-analysis. J Addict Res Ther [Internet]. 2015 [cited 2022 Apr 10];06. Available from: https://www.omicsonline.org/open-access/drug-abuse-in-people-living-with-hiv-in-the-era-of-highly-active-antiretroviral-therapy-a-systematic-review-and-metaanalysis-2155-6105-1000255.php?aid=66245

  57. Doria de Vasconcellos H, Post WS, Ervin A-M, Haberlen SA, Budoff M, Malvestutto C, et al. Associations between HIV serostatus and cardiac structure and function evaluated by 2-dimensional echocardiography in the multicenter AIDS cohort study. J Am Heart Assoc. 2021;10:e019709.

  58. Roozen GVT, Meel R, Peper J, Venter WDF, Barth RE, Grobbee DE, et al. Electrocardiographic and echocardiographic abnormalities in urban African people living with HIV in South Africa. PLoS ONE. 2021;16: e0244742.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Woldu B, Temu TM, Kirui N, Christopher B, Ndege S, Post WS, et al. Diastolic dysfunction in people with HIV without known cardiovascular risk factors in Western Kenya. Open Heart. 2022;9: e001814.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Mahtab S, Lawrenson J, Jamieson-Luff N, Asafu-Agyei NA, Meiring A, Lemmer-Hunsinger C, et al. Echocardiographic findings in a cohort of perinatally HIV-infected adolescents compared with uninfected peers from the Cape Town adolescent antiretroviral cohort. J Am Soc Echocardiogr. 2020;33:604–11.

    Article  PubMed  Google Scholar 

  61. Duncan MS, Alcorn CW, Freiberg MS, So-Armah K, Patterson OV, DuVall SL, et al. Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. Lancet Healthy Longev. 2021;2:e417–25.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Holloway CJ, Ntusi N, Suttie J, Mahmod M, Wainwright E, Clutton G, et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation. 2013;128:814–22.

    Article  PubMed  Google Scholar 

  63. Ntusi N, O’Dwyer E, Dorrell L, Wainwright E, Piechnik S, Clutton G, et al. HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema. Circ Cardiovasc Imaging. 2016;9: e004430.

    Article  PubMed  Google Scholar 

  64. Thiara DK, Liu CY, Raman F, Mangat S, Purdy JB, Duarte HA, et al. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis. 2015;212:1544–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. de Leuw P, Arendt CT, Haberl AE, Froadinadl D, Kann G, Wolf T, et al. Myocardial fibrosis and inflammation by CMR predict cardiovascular outcome in people living with HIV. JACC Cardiovasc Imaging. 2021;14:1548–57.

    Article  PubMed  Google Scholar 

  66. Neilan TG, Nguyen K-L, Zaha VG, Chew KW, Morrison L, Ntusi NAB, et al. Myocardial steatosis among antiretroviral therapy-treated people with human immunodeficiency virus participating in the REPRIEVE trial. J Infect Dis. 2020;222:S63–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Wu KC, Haberlen SA, Plankey MW, Palella FJ, Piggott DA, Kirk GD, et al. Human immunodeficiency viral infection and differences in interstitial ventricular fibrosis and left atrial size. Eur Heart J Cardiovasc Imaging. 2021;22:888–95.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24:243–53.

    Article  PubMed  Google Scholar 

  69. Post WS, Budoff M, Kingsley L, Palella FJ, Witt MD, Li X, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. American College of Physicians; 2014;160:458–67.

  70. Kingsley LA, Deal J, Jacobson L, Budoff M, Witt M, Palella F, et al. Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men. AIDS. 2015;29:2427–34.

    Article  CAS  PubMed  Google Scholar 

  71. Post W, Haberlen HS, Witt MD, Zhang Long, Jacobson LP, Brown TT, et al. Suboptimal HIV suppression is associated with progression of coronary artery stenosis: the multicenter AIDS cohort study (MACS) longitudinal coronary CT angiography study. AIDS (London, England).

  72. Feinstein MJ. Cardiovascular disease risk assessment in HIV: navigating data-sparse zones. Heart. 2016;102:1157–8.

    Article  PubMed  Google Scholar 

  73. Hsue PY, Waters DD. Time to recognize HIV infection as a major cardiovascular risk factor. Circulation. 2018;138:1113–5.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140:e98-124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation. 2018;137:2203–14.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.

    Article  CAS  PubMed  Google Scholar 

  77. Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23:214–23.

    Article  PubMed  Google Scholar 

  78. Ryom L, Cotter A, De Miguel R, Béguelin C, Podlekareva D, Arribas JR, et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med. 2020;21:617–24.

  79. Myerson M, Malvestutto C, Aberg JA. Management of lipid disorders in patients living with HIV. J Clin Pharmacol. 2015;55:957–74.

    Article  PubMed  Google Scholar 

  80. Okello S, Amir A, Bloomfield GS, Kentoffio K, Lugobe HM, Reynolds Z, et al. Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa. Prog Cardiovasc Dis. 2020;63:149–59.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Ojo T, Lester L, Iwelunmor J, Gyamfi J, Obiezu-Umeh C, Onakomaiya D, et al. Feasibility of integrated, multilevel care for cardiovascular diseases (CVD) and HIV in low- and middle-income countries (LMICs): A scoping review. PLoS ONE. 2019;14: e0212296.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, et al. Cardiovascular risk and health among people with human immunodeficiency Virus (HIV) eligible for primary prevention: insights from the REPRIEVE Trial. Clin Infect Dis. 2021;73:2009–22.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, et al. Safety and impact of low-dose methotrexate on endothelial function and inflammation in individuals with treated human immunodeficiency virus: AIDS Clinical Trials Group Study A5314. Clin Infect Dis. 2019;68:1877–86.

    Article  CAS  PubMed  Google Scholar 

  84. Hays AG, Schär M, Barditch-Crovo P, Bagchi S, Bonanno G, Meyer J, et al. A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV. AIDS. 2021;35:1041–50.

    Article  CAS  PubMed  Google Scholar 

  85. Hsue PY, Li D, Ma Y, Ishai A, Manion M, Nahrendorf M, et al. IL-1β inhibition reduces atherosclerotic inflammation in HIV infection. J Am Coll Cardiol. 2018;72:2809–11.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Leucker TM, Gerstenblith G, Schär M, Brown TT, Jones SR, Afework Y, et al. Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia. J Am Heart Assoc. 2020;9: e016263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Johns Hopkins Division of Cardiology, Baltimore, MD, USA

    Anjali Wagle, Erin Goerlich, Wendy S. Post, Bethel Woldu, Katherine C. Wu & Allison G. Hays

  2. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Wendy S. Post, Katherine C. Wu & Allison G. Hays

  3. MedStar Heart and Vascular Institute, Baltimore, MD, USA

    Bethel Woldu

  4. Department of Medicine, Division of Cardiology, MedStar Georgetown University, Washington, DC, USA

    Bethel Woldu

Authors
  1. Anjali Wagle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin Goerlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wendy S. Post
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bethel Woldu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katherine C. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Allison G. Hays
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allison G. Hays.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Global Cardiovascular Health

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wagle, A., Goerlich, E., Post, W.S. et al. HIV and Global Cardiovascular Health. Curr Cardiol Rep 24, 1149–1157 (2022). https://doi.org/10.1007/s11886-022-01741-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-022-01741-1

Keywords

Search

Navigation